Archives: 2019-05-09

Oversight of Regenerative Medicine: FDA’s new regulatory approach

Regenerative medicine—a field that includes stem cells, bioengineered tissues, and gene therapies—holds great potential. In November 2017, the Food and Drug Administration updated its regulatory framework for these products. Peter Marks, who leads the agency’s Center for Biologics Evaluation and Research (CBER), about the framework gave this interview. Q: What led FDA to update its regulatory framework

Read More


A mysterious dementia that mimics Alzheimer’s gets named LATE

A newly described dementia strikes people in their last decades of life. The disease, aptly named LATE, comes with symptoms that resemble Alzheimer’s disease, but is thought to be caused by something completely different. An international team of scientists and clinicians describe the disease and officially christen it LATE, which stands for the more technical description,

Read More


JAMA Counteracting Health Misinformation A Role for Medical Journals?

A recent editorial in the Journal of the American Medical Association (JAMA) addresses the growing problem of medical misinformation, such as anti-vaccine views, fake treatments, unproven alternative products and services, and others. The authors, Armstrong and Naylor, make some good recommendations, but unfortunately are about 20 years behind the times when it comes to confronting scientific misinformation.

Read More